NRF2 overactivation by early growth response 1 (EGR1) leads to increased HMOX1 transcription in breast cancer, providing a survival advantage to the cancer cells and promoting resistance to therapy (65). This evidence concerns the gene NFE2L2 and breast carcinoma.